Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.
OBJECTIVE
This retrospective multicenter study assessed the outcome of 51 patients with myeloid sarcoma (MS) who underwent allogeneic hematopoietic stem-cell transplantation (alloHSCT).


METHODS
Most patients had MS presenting in conjunction with acute myeloid leukemia (AML) or after AML. Six patients had isolated MS. The median time between diagnosis and alloHSCT was 8 months (range, 2.8 to 67). Forty patients were in complete remission (CR) at time of alloHSCT.


RESULTS
With a median follow-up of 33 (range, 1 to 182) months, the Kaplan-Meier estimates of overall survival (OS) and disease-free survival were 47% (95% CI, 33% to 61%) and 36% (95% CI, 24% to 50%) at 5 years. Twenty patients (39%) relapsed at a median of 204 (range, 35 to 1151) days after alloHSCT, with relapse being the major cause of death. In a Cox multivariate analysis, age > or = 15 years and remission status at time of alloHSCT (CR v other) were associated with improved OS (hazard ratio [HR], 0.27; 95% CI, 0.12 to 0.65; P = .003; and HR, 0.22; 95% CI, 0.08 to 0.57; P = .002, respectively).


CONCLUSIONS
We conclude that first-line alloHSCT performed early in the course of MS is a valid therapeutic option.
Chevallier
Patrice
P
Centre Hospitalier Universitaire (CHU) Hôtel-Dieu, Cellule de Promotion à la Recherche Clinique, CHU Hotel-Dieu, Nantes, France. patrice.chevallier@chu-nantes.fr
Mohty
Mohamad
M
Lioure
Bruno
B
Michel
Gerard
G
Contentin
Nathalie
N
Deconinck
Eric
E
Bordigoni
Pierre
P
Vernant
Jean-Paul
JP
Hunault
Mathilde
M
Vigouroux
Stéphane
S
Blaise
Didier
D
Tabrizi
Reza
R
Buzyn
Agnes
A
Socie
Gerard
G
Michallet
Mauricette
M
Volteau
Christelle
C
Harousseau
Jean-Luc
JL
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D023981:Sarcoma, Myeloid / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome